Modulation and modeling of monoclonal antibody N-linked glycosylation in mammalian cell perfusion reactors
- PMID: 28409838
- DOI: 10.1002/bit.26315
Modulation and modeling of monoclonal antibody N-linked glycosylation in mammalian cell perfusion reactors
Abstract
Mammalian cell perfusion cultures are gaining renewed interest as an alternative to traditional fed-batch processes for the production of therapeutic proteins, such as monoclonal antibodies (mAb). The steady state operation at high viable cell density allows the continuous delivery of antibody product with increased space-time yield and reduced in-process variability of critical product quality attributes (CQA). In particular, the production of a confined mAb N-linked glycosylation pattern has the potential to increase therapeutic efficacy and bioactivity. In this study, we show that accurate control of flow rates, media composition and cell density of a Chinese hamster ovary (CHO) cell perfusion bioreactor allowed the production of a constant glycosylation profile for over 20 days. Steady state was reached after an initial transition phase of 6 days required for the stabilization of extra- and intracellular processes. The possibility to modulate the glycosylation profile was further investigated in a Design of Experiment (DoE), at different viable cell density and media supplement concentrations. This strategy was implemented in a sequential screening approach, where various steady states were achieved sequentially during one culture. It was found that, whereas high ammonia levels reached at high viable cell densities (VCD) values inhibited the processing to complex glycan structures, the supplementation of either galactose, or manganese as well as their synergy significantly increased the proportion of complex forms. The obtained experimental data set was used to compare the reliability of a statistical response surface model (RSM) to a mechanistic model of N-linked glycosylation. The latter outperformed the response surface predictions with respect to its capability and reliability in predicting the system behavior (i.e., glycosylation pattern) outside the experimental space covered by the DoE design used for the model parameter estimation. Therefore, we can conclude that the modulation of glycosylation in a sequential steady state approach in combination with mechanistic model represents an efficient and rational strategy to develop continuous processes with desired N-linked glycosylation patterns. Biotechnol. Bioeng. 2017;114: 1978-1990. © 2017 Wiley Periodicals, Inc.
Keywords: N-linked glycosylation; mammalian cell culture; mathematical model; monoclonal antibody; perfusion bioreactor.
© 2017 Wiley Periodicals, Inc.
Similar articles
-
Temporal Galactose-Manganese Feeding in Fed-Batch and Perfusion Bioreactors Modulates UDP-Galactose Pools for Enhanced mAb Glycosylation Homogeneity.Biotechnol Bioeng. 2025 Jul;122(7):1710-1723. doi: 10.1002/bit.28999. Epub 2025 Apr 18. Biotechnol Bioeng. 2025. PMID: 40251805 Free PMC article.
-
Process performance and product quality in an integrated continuous antibody production process.Biotechnol Bioeng. 2017 Feb;114(2):298-307. doi: 10.1002/bit.26069. Epub 2016 Aug 17. Biotechnol Bioeng. 2017. PMID: 27497430
-
Controlling the time evolution of mAb N-linked glycosylation - Part II: Model-based predictions.Biotechnol Prog. 2016 Sep;32(5):1135-1148. doi: 10.1002/btpr.2315. Epub 2016 Jul 1. Biotechnol Prog. 2016. PMID: 27273889
-
Recent advances in the understanding of biological implications and modulation methodologies of monoclonal antibody N-linked high mannose glycans.Biotechnol Bioeng. 2014 Oct;111(10):1907-19. doi: 10.1002/bit.25318. Epub 2014 Aug 7. Biotechnol Bioeng. 2014. PMID: 24975601 Review.
-
N-Glycosylation Design and Control of Therapeutic Monoclonal Antibodies.Trends Biotechnol. 2016 Oct;34(10):835-846. doi: 10.1016/j.tibtech.2016.02.013. Epub 2016 Mar 22. Trends Biotechnol. 2016. PMID: 27016033 Review.
Cited by
-
Truly continuous low pH viral inactivation for biopharmaceutical process integration.Biotechnol Bioeng. 2020 May;117(5):1406-1417. doi: 10.1002/bit.27292. Epub 2020 Feb 24. Biotechnol Bioeng. 2020. PMID: 32017010 Free PMC article.
-
Temporal Galactose-Manganese Feeding in Fed-Batch and Perfusion Bioreactors Modulates UDP-Galactose Pools for Enhanced mAb Glycosylation Homogeneity.Biotechnol Bioeng. 2025 Jul;122(7):1710-1723. doi: 10.1002/bit.28999. Epub 2025 Apr 18. Biotechnol Bioeng. 2025. PMID: 40251805 Free PMC article.
-
Developments and opportunities in continuous biopharmaceutical manufacturing.MAbs. 2021 Jan-Dec;13(1):1903664. doi: 10.1080/19420862.2021.1903664. MAbs. 2021. PMID: 33843449 Free PMC article. Review.
-
Perfusion Process Intensification for Lentivirus Production Using a Novel Scale-Down Model.Biotechnol Bioeng. 2025 Feb;122(2):344-360. doi: 10.1002/bit.28880. Epub 2024 Nov 13. Biotechnol Bioeng. 2025. PMID: 39535315 Free PMC article.
-
Harnessing the potential of artificial neural networks for predicting protein glycosylation.Metab Eng Commun. 2020 May 15;10:e00131. doi: 10.1016/j.mec.2020.e00131. eCollection 2020 Jun. Metab Eng Commun. 2020. PMID: 32489858 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources